1-5 of 5
Malcolm Moore
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer

Free
Margaret A. Tempero, David Klimstra, Jordan Berlin, Tony Hollingsworth, Paula Kim, Nipun Merchant, Malcolm Moore, Doug Pleskow, Andrea Wang-Gillam, Andrew M. Lowy
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (3): 538–540.
https://doi.org/10.1158/1078-0432.CCR-12-2745
Published: 31 January 2013
View articletitled, Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer
Open the PDF for Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer in another window
Journal Articles

Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent

Free
Anthony J. Mutsaers, Giulio Francia, Shan Man, Christina R. Lee, John M.L. Ebos, Yan Wu, Larry Witte, Scott Berry, Malcolm Moore, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2397–2405.
https://doi.org/10.1158/1078-0432.CCR-08-1627
Published: 01 April 2009
View articletitled, Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent
Open the PDF for Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent in another window
Journal Articles

Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer

Free
Howard L. Kaufman, Heinz-Josef Lenz, John Marshall, Deepti Singh, Chris Garett, Christine Cripps, Malcolm Moore, Margaret von Mehren, Richard Dalfen, William J. Heim, Robert M. Conry, Walter J. Urba, Al B. Benson, III, Maria Yu, Judy Caterini, Seunghee Kim-Schulze, Mark DeBenedette, Danielle Salha, Thorsten Vogel, Ileana Elias, Neil L. Berinstein
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15): 4843–4849.
https://doi.org/10.1158/1078-0432.CCR-08-0276
Published: 01 August 2008
View articletitled, Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
Open the PDF for Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer in another window
Journal Articles

A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer

Free
Helen Mackay, David Hedley, Pierre Major, Carol Townsley, Mary Mackenzie, Mark Vincent, Pam Degendorfer, Ming-Sound Tsao, Trudey Nicklee, Diana Birle, John Wright, Lillian Siu, Malcolm Moore, Amit Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5526–5533.
https://doi.org/10.1158/1078-0432.CCR-05-0081
Published: 01 August 2005
View articletitled, A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer
Open the PDF for A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer in another window
Journal Articles

A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer

Free
Anthony W. Tolcher, Leonard Reyno, Peter M. Venner, Scott D. Ernst, Malcolm Moore, Richard S. Geary, Kim Chi, Sean Hall, Wendy Walsh, Andrew Dorr, Elizabeth Eisenhauer
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (8): 2530–2535.
Published: 01 August 2002
View articletitled, A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer
Open the PDF for A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer in another window